Media coverage about Chemed (NYSE:CHE) has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chemed earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.1430786508601 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Chemed (NYSE CHE) traded down $1.95 during midday trading on Friday, hitting $262.16. The stock had a trading volume of 97,510 shares, compared to its average volume of 82,475. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.48 and a current ratio of 0.50. The firm has a market capitalization of $4,216.78, a P/E ratio of 58.26, a PEG ratio of 2.96 and a beta of 1.16. Chemed has a fifty-two week low of $163.50 and a fifty-two week high of $266.31.
Chemed (NYSE:CHE) last issued its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.15. The business had revenue of $417.40 million during the quarter, compared to the consensus estimate of $414.34 million. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The business’s revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.73 earnings per share. equities research analysts forecast that Chemed will post 4.73 earnings per share for the current year.
A number of equities analysts have commented on the company. Oppenheimer lifted their target price on Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Zacks Investment Research upgraded Chemed from a “hold” rating to a “buy” rating and set a $216.00 price objective for the company in a research report on Monday, September 18th. ValuEngine downgraded Chemed from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Royal Bank of Canada reiterated a “hold” rating and set a $209.00 price objective on shares of Chemed in a research report on Tuesday, October 3rd. Finally, TheStreet upgraded Chemed from a “c+” rating to an “a-” rating in a research report on Friday, October 27th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $236.00.
In other Chemed news, insider David Patrick Williams sold 11,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $241.28, for a total value of $2,654,080.00. Following the completion of the sale, the insider now directly owns 74,857 shares in the company, valued at $18,061,496.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin J. Mcnamara sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $223.42, for a total value of $2,234,200.00. Following the completion of the sale, the chief executive officer now owns 170,016 shares of the company’s stock, valued at $37,984,974.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 45,679 shares of company stock valued at $10,628,959. Insiders own 4.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Chemed (CHE) Earning Somewhat Favorable Media Coverage, Study Shows” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/chemed-che-earning-somewhat-favorable-media-coverage-study-shows.html.
Chemed Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.